Abstract

Aims The goal of this study was to evaluate the effects of long-term (16 weeks) administration of angiotensin (1–7) [A(1–7)] on kidney function in db/db mice and to identify the protective mechanisms of this therapy. Methods db/db mice and heterozygous controls were treated with A(1–7) or vehicle daily, subcutaneously for up to 16 weeks. Kidney injury was assessed by measuring blood flow in renal arteries, plasma creatinine levels, and proteinuria. Effects of treatment on oxidative stress were evaluated by histological staining and gene expression. Results 16 weeks of daily administration of A(1–7) to a mouse model of severe type 2 diabetes (db/db) prevented the progression of kidney damage. Treatment with A(1–7) improved blood flow in the renal arteries, as well as decreased plasma creatinine levels and proteinuria in diabetic mice. Reduction of oxidative stress was identified as one of the mechanisms of the renoprotective action of A(1–7). Treatment prevented formation of nitrotyrosine residues, a marker of oxidative stress damage. A(1–7) also reduced the expression of two enzymes involved in formation of nitrotyrosine, namely, eNOS and NOX-4. A(1–7) regulated the phosphorylation pattern of eNOS to enhance production of NO in diabetic animals, possibly through the Akt pathway. However, these elevated levels of NO did not result in increased nitrosylation, possibly due to reduced NOX-4 levels. Conclusions Long-term administration of A(1–7) improved kidney function and reduced oxidative stress damage in db/db mice.

Highlights

  • Over 100,000 US citizens are diagnosed with kidney failure yearly and 44% of them are due to diabetes [1]

  • The current treatment for diabetic nephropathy focuses on angiotensin-converting enzyme inhibitors (ACEi), which reduce the production of angiotensin II (Ang-II), and angiotensin receptor blockers (ARBs), which block the actions of Ang-II through its cognate receptor, AT1

  • It is hypothesized that angiotensin (1–7) [A(1–7)], another member of the renin-angiotensin system (RAS), can ameliorate diabetic nephropathy without the side effects of ACEi or ARBs

Read more

Summary

Introduction

Over 100,000 US citizens are diagnosed with kidney failure yearly and 44% of them are due to diabetes [1]. The current treatment for diabetic nephropathy focuses on angiotensin-converting enzyme inhibitors (ACEi), which reduce the production of Ang-II, and angiotensin receptor blockers (ARBs), which block the actions of Ang-II through its cognate receptor, AT1. Both therapies are associated with adverse effects, are not safe to use during pregnancy [10, 11], and do not completely eliminate kidney damage. It is hypothesized that angiotensin (1–7) [A(1–7)], another member of the RAS, can ameliorate diabetic nephropathy without the side effects of ACEi or ARBs. A(1–7) has been shown to decrease hypertension and oppose pathological actions of Ang-II [12, 13]. We demonstrate that long-term administration of A(1–7) to db/db mice, a model of severe T2D, acts renoprotective, at least in part, through the amelioration of oxidative stress

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call